

# Mariagrazia Rumi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5208557/publications.pdf>

Version: 2024-02-01

125  
papers

5,502  
citations

109137

35  
h-index

85405

71  
g-index

126  
all docs

126  
docs citations

126  
times ranked

5809  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. <i>Journal of Hepatology</i> , 1996, 24, 38-47.   | 1.8 | 485       |
| 2  | The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. <i>Gut</i> , 2010, 59, 638-644.                                   | 6.1 | 358       |
| 3  | A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. <i>Hepatology</i> , 2012, 56, 532-543.          | 3.6 | 354       |
| 4  | A 28-Year Study of the Course of Hepatitis B Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2009, 136, 1629-1638.                                    | 0.6 | 285       |
| 5  | High rates of 30-day mortality in patients with cirrhosis and COVID-19. <i>Journal of Hepatology</i> , 2020, 73, 1063-1071.  | 1.8 | 279       |
| 6  | Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. <i>Hepatology</i> , 2011, 53, 791-799.  | 3.6 | 227       |
| 7  | Randomized Study of Peginterferon-2a Plus Ribavirin vs Peginterferon-2b Plus Ribavirin in Chronic Hepatitis C. <i>Gastroenterology</i> , 2010, 138, 108-115.   | 0.6 | 190       |
| 8  | Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006, 43, 64-71.  | 3.6 | 163       |
| 9  | The diagnostic accuracy of Fibroscan® for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. <i>Journal of Hepatology</i> , 2013, 59, 251-256.      | 1.8 | 131       |
| 10 | High Prevalence of Antibody to Hepatitis C Virus in Multitransfused Hemophiliacs with Normal Transaminase Levels. <i>Annals of Internal Medicine</i> , 1990, 112, 379.                               | 2.0 | 129       |
| 11 | A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. <i>Blood</i> , 2003, 102, 78-82.                                      | 0.6 | 119       |
| 12 | Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. <i>Hepatology</i> , 2011, 54, 1127-1134. | 3.6 | 115       |
| 13 | A multicenter randomized controlled trial of recombinant interferon-2b in patients with acute transfusion-associated hepatitis C. <i>Hepatology</i> , 1994, 19, 19-22.                               | 3.6 | 110       |
| 14 | Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. <i>Journal of Hepatology</i> , 2011, 54, 621-628.   | 1.8 | 110       |
| 15 | Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2019, 70, 379-387.  | 1.8 | 109       |
| 16 | Long-term delta superinfection in hepatitis B surface antigen carriers and its relationship to the course of chronic hepatitis. <i>Gastroenterology</i> , 1983, 85, 235-239.                         | 0.6 | 96        |
| 17 | Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. <i>Journal of Hepatology</i> , 2004, 41, 474-481.                        | 1.8 | 91        |
| 18 | Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. <i>Hepatology</i> , 2012, 56, 1681-1687.   | 3.6 | 83        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. <i>Hepatology</i> , 2012, 55, 336-342.  | 3.6 | 81        |
| 20 | Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. <i>Journal of Hepatology</i> , 1996, 24, 517-524.  | 1.8 | 76        |
| 21 | Hepatitis C virus RNA profiles in chronically infected individuals: Do they relate to disease activity?. <i>Hepatology</i> , 1999, 29, 585-589.  | 3.6 | 76        |
| 22 | Specificity of hepatitis C antibody ELISA in patients with haemophilia. <i>Lancet</i> , The, 1990, 335, 1345.  | 6.3 | 67        |
| 23 | Pegylated interferons $\alpha$ 2a and $\alpha$ 2b in the treatment of chronic hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 485-494.   | 8.2 | 62        |
| 24 | Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. <i>Gut</i> , 2005, 54, 402-406.  | 6.1 | 61        |
| 25 | Long-term response to interferon alpha is unrelated to interferon sensitivity determining region variability in patients with chronic hepatitis C virus-1b infection. <i>Journal of Hepatology</i> , 1999, 30, 1023-1027.  | 1.8 | 52        |
| 26 | Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. <i>Journal of Hepatology</i> , 2013, 59, 38-44.   | 1.8 | 52        |
| 27 | The Course of Esophageal Varices in Patients with Hepatitis C Cirrhosis Responding to Interferon/Ribavirin Therapy. <i>Antiviral Therapy</i> , 2011, 16, 677-684.  | 0.6 | 48        |
| 28 | Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. <i>Transfusion</i> , 1995, 35, 209-212.  | 0.8 | 45        |
| 29 | A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. <i>Blood</i> , 1997, 89, 3529-33. | 0.6 | 44        |
| 30 | Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0172159.  | 1.1 | 42        |
| 31 | Performance of the COBAS AMPLICOR HCV MONITOR Test, Version 2.0, an Automated Reverse Transcription-PCR Quantitative System for Hepatitis C Virus Load Determination. <i>Journal of Clinical Microbiology</i> , 2000, 38, 2210-2214.   | 1.8 | 40        |
| 32 | Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. <i>Journal of Hepatology</i> , 1996, 24, 33-37.   | 1.8 | 39        |
| 33 | TT Virus Is Present in a High Frequency of Italian Hemophilic Patients Transfused With Plasma-Derived Clotting Factor Concentrates. <i>Blood</i> , 1999, 94, 4333-4336.  | 0.6 | 39        |
| 34 | Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 593-602.  | 1.8 | 38        |
| 35 | Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.  | 1.1 | 37        |
| 36 | Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. <i>Journal of Viral Hepatitis</i> , 2002, 9, 71-74.  | 1.0 | 36        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Suboptimal Response to Hepatitis B Vaccine in Drug Users. <i>Archives of Internal Medicine</i> , 1991, 151, 574.  | 4.3 | 35        |
| 38 | Implications of <i>PNPLA3</i> polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1434-1442.                                       | 1.9 | 35        |
| 39 | Natural History and Clinical Impact of Cryoglobulins in Chronic Hepatitis C: 10-Year Prospective Study of 343 Patients. <i>Gastroenterology</i> , 2007, 133, 835-842.   | 0.6 | 34        |
| 40 | Hepatitis C antibody in patients with chronic liver disease and hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1130-1133.   | 1.1 | 33        |
| 41 | Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. <i>Journal of Viral Hepatitis</i> , 2013, 20, 858-866.   | 1.0 | 32        |
| 42 | The pattern of pegylated interferon- $\alpha$ 2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. <i>Antiviral Therapy</i> , 2009, 14, 577-584.                                     | 0.6 | 30        |
| 43 | HLA-DR Antigens in HBsAg-Positive Chronic Active Liver Disease with and without Associated Delta Infection. <i>Hepatology</i> , 1984, 4, 1107-1110.   | 3.6 | 27        |
| 44 | Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. <i>Blood</i> , 2002, 99, 1089-1091.   | 0.6 | 27        |
| 45 | Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. <i>Gut</i> , 2002, 51, 864-869.   | 6.1 | 26        |
| 46 | Persistence of "wild-type" and "e-minus" hepatitis B virus infection in chronic healthy HBsAg/anti-HBe positive carriers. <i>Journal of Hepatology</i> , 1994, 20, 148-151.   | 1.8 | 24        |
| 47 | Hepatitis C in haemophilia: lights and shadows. <i>Haemophilia</i> , 2004, 10, 211-215.   | 1.0 | 24        |
| 48 | Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. <i>European Journal of Internal Medicine</i> , 2008, 19, 370-371.  | 1.0 | 24        |
| 49 | Onset of inflammatory bowel diseases during combined $\alpha$ -interferon and ribavirin therapy for chronic hepatitis C: report of two cases. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1243-1245. | 0.8 | 23        |
| 50 | Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. <i>PLoS ONE</i> , 2016, 11, e0155967.   | 1.1 | 23        |
| 51 | Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to $\alpha$ IFN and cirrhosis regression. <i>Liver International</i> , 2018, 38, 1459-1467.  | 1.9 | 22        |
| 52 | Accelerated schedule of hepatitis B vaccination in patients with hemophilia. <i>Journal of Medical Virology</i> , 1993, 41, 95-98.  | 2.5 | 21        |
| 53 | Serum Levels of Hepatitis C Virus Core Antigen as a Marker of Infection and Response to Therapy. <i>American Journal of Gastroenterology</i> , 2004, 99, 1738-1743.   | 0.2 | 21        |
| 54 | Hyporesponsiveness to PegIFN $\alpha$ 2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. <i>Journal of Hepatology</i> , 2012, 56, 341-347.   | 1.8 | 21        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | High Rates of Hepatitis G Virus Infection in Multitransfused Patients With Hemophilia. <i>Blood</i> , 1997, 90, 4634-4637.  | 0.6 | 20        |
| 56 | Hepatitis C virus genotype 1b and risk of hepatocellular carcinoma. <i>Hepatology</i> , 1997, 26, 1077-1077.  | 3.6 | 20        |
| 57 | Primary prophylaxis of variceal bleeding in cirrhotic patients: A cohort study. <i>Digestive and Liver Disease</i> , 2008, 40, 936-943.   | 0.4 | 20        |
| 58 | Long-term titrated recombinant interferon- $\alpha$ 2a in chronic hepatitis C: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 1995, 2, 73-76.   | 1.0 | 19        |
| 59 | Pegylated IFN- $\alpha$ 2a and ribavirin in the treatment of hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 925-935.  | 2.0 | 19        |
| 60 | The Association of IL28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent. <i>International Journal of Molecular Sciences</i> , 2014, 15, 7213-7224.                            | 1.8 | 19        |
| 61 | <i>in vitro</i> HCV E1E2- $\Delta$ MF-59 vaccine in chronic hepatitis C patients treated with PEG-IFN- $\alpha$ 2a and ribavirin: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2014, 21, 458-465. | 1.0 | 19        |
| 62 | High Rates of Hepatitis G Virus Infection in Multitransfused Patients With Hemophilia. <i>Blood</i> , 1997, 90, 4634-4637.  | 0.6 | 19        |
| 63 | US Features of Liver Surface Nodularity as a Predictor of Severe Fibrosis in Chronic Hepatitis C. <i>Radiology</i> , 2005, 234, 641-641.  | 3.6 | 18        |
| 64 | HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C. <i>Journal of Hepatology</i> , 2009, 51, 964-966.  | 1.8 | 18        |
| 65 | Telaprevir in a Patient with Chronic Hepatitis C and Cryoglobulinemic Glomerulonephritis. <i>Antiviral Therapy</i> , 2014, 19, 527-531.   | 0.6 | 18        |
| 66 | Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2019, 51, 1135-1140.                                    | 0.4 | 18        |
| 67 | High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. <i>Haematologica</i> , 2006, 91, 1367-71.   | 1.7 | 18        |
| 68 | Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon. <i>Journal of Viral Hepatitis</i> , 1995, 2, 251-256.   | 1.0 | 17        |
| 69 | Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor. <i>Transfusion</i> , 1998, 38, 307-311.  | 0.8 | 16        |
| 70 | The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. <i>Antiviral Therapy</i> , 2009, 14, 577-84.                                   | 0.6 | 16        |
| 71 | Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. <i>Transfusion</i> , 2004, 44, 790-794.  | 0.8 | 15        |
| 72 | The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. <i>Antiviral Therapy</i> , 2009, 14, 789-796.  | 0.6 | 15        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Impaired Response to Interferon-Î±2B plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection. <i>Antiviral Therapy</i> , 2006, 11, 797-802.  | 0.6 | 15        |
| 74 | Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients. <i>Blood</i> , 1990, 75, 1654-1658.   | 0.6 | 14        |
| 75 | Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity. <i>PLoS ONE</i> , 2015, 10, e0138546.       | 1.1 | 14        |
| 76 | Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir. <i>PLoS ONE</i> , 2014, 9, e95881.   | 1.1 | 13        |
| 77 | A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.   | 3.6 | 12        |
| 78 | Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion.. <i>Gut</i> , 1993, 34, S141-S141.   | 6.1 | 11        |
| 79 | Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2014, 21, 416-423.   | 1.0 | 11        |
| 80 | Management of HCV-Related Liver Disease in Hemophilia and Thalassemia. <i>Seminars in Liver Disease</i> , 2018, 38, 112-120.   | 1.8 | 11        |
| 81 | Minimal increases of serum alpha-fetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy. <i>Liver International</i> , 2019, 39, 1964-1974.  | 1.9 | 11        |
| 82 | Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma. <i>Digestive and Liver Disease</i> , 2019, 51, 719-723.  | 0.4 | 11        |
| 83 | Alpha interferon treatment of chronic hepatitis C. <i>Biomedicine and Pharmacotherapy</i> , 1995, 49, 111-115.   | 2.5 | 10        |
| 84 | Ribavirin Impairs Salivary Gland Function in Hepatitis C Patients During Combination Treatment With Pegylated Interferon Alfa-2a. <i>Hepatitis Monthly</i> , 2011, 11, 918-924.  | 0.1 | 10        |
| 85 | Treatment of chronic hepatitis C in Europe. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2003, 10, 168-171.   | 2.0 | 9         |
| 86 | Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy. <i>Hepatology</i> , 2010, 52, 1170-1171.  | 3.6 | 9         |
| 87 | Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. <i>Digestive and Liver Disease</i> , 2019, 51, 419-424.   | 0.4 | 9         |
| 88 | Serum levels of hepatitis C virus RNA predict non-response to interferon therapy: comparison of two commercial assays. <i>Journal of Viral Hepatitis</i> , 1999, 6, 65-71.   | 1.0 | 8         |
| 89 | Hepatitis A virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1997-2005. | 1.9 | 8         |
| 90 | Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.  | 1.9 | 8         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | The Prevalence, Clinical Features and Response to Antiviral Therapy of Patients with Chronic Hepatitis C who are Seropositive for Liverâ€™Kidney Microsome Type 1 Antibodies. <i>Antiviral Therapy</i> , 2005, 10, 715-720.          | 0.6 | 8         |
| 92  | Lack of Rapid Virological Response Predicts Interferon-Î±2b/Ribavirin Therapy failure in HCV Genotype 2 Patients: A Single-Centre Study. <i>Antiviral Therapy</i> , 2007, 12, 1033-1040.   | 0.6 | 8         |
| 93  | Acute Hepatitis B in Children with Papular Acrodermatitis. <i>Pediatric Pathology</i> , 1986, 6, 249-257.  | 0.5 | 7         |
| 94  | Antiviral Therapy for HCV-Associated Cryoglobulinemic Glomerulonephritis: Case Report and Review of the Literature. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 687-693.   | 0.9 | 7         |
| 95  | Comparative trials of peginterferon Î±2a and peginterferon Î±2b for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 37-41.  | 1.0 | 7         |
| 96  | Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 431-439.                       | 1.9 | 7         |
| 97  | Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients. <i>Hepatitis Monthly</i> , 2011, 11, 918-924.  | 0.1 | 7         |
| 98  | Direct detection of HBV preC mutants in heterogeneous viral populations by a modified DNA sequencing method. <i>Research in Virology</i> , 1993, 144, 303-306.   | 0.7 | 6         |
| 99  | Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1067-1076. | 1.8 | 6         |
| 100 | Interleukin 28B Genotype and Insulin Resistance in Chronic Hepatitis C Patients. <i>Antiviral Therapy</i> , 2014, 19, 747-753.   | 0.6 | 6         |
| 101 | Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study. <i>Hepatology Communications</i> , 2022, 6, 867-877.   | 2.0 | 6         |
| 102 | Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. <i>Antiviral Therapy</i> , 2006, 11, 797-802.   | 0.6 | 6         |
| 103 | Pegylated interferon Î±2b versus pegylated interferon Î±2a for chronic hepatitis C: The unreached goal of superiority. <i>Journal of Hepatology</i> , 2009, 51, 1097-1099.   | 1.8 | 4         |
| 104 | A multicenter randomized controlled trial of recombinant interferon-Î±2b in patients with acute transfusion-associated hepatitis C. <i>Hepatology</i> , 1994, 19, 19-22.   | 3.6 | 4         |
| 105 | Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients. <i>Blood</i> , 1990, 75, 1654-8.  | 0.6 | 4         |
| 106 | Anti-LAV/HTLV-III antibodies in groups of individuals at high risk for infection in Italy. <i>Research in Clinic and Laboratory</i> , 1985, 15, 357-364.   | 0.3 | 4         |
| 107 | Hepatitis C virus screening in the 1969â€™1989 birth cohort: Is not enough!. <i>Liver International</i> , 2022, 42, 1915-1915.   | 1.9 | 4         |
| 108 | Immunogenicity of a yeast-recombinant hepatitis B vaccine in high-risk children. <i>Journal of Medical Virology</i> , 1989, 27, 48-51.   | 2.5 | 3         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Specificity of the Hepatitis C Virus Antibody ELISA in Patients With Hepatocellular Carcinoma. Journal of the National Cancer Institute, 1990, 82, 1784-1785.   | 3.0 | 3         |
| 110 | Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients. BioMed Research International, 2013, 2013, 1-6.                                 | 0.9 | 3         |
| 111 | Development of antibody to hepatitis C virus (HCV) in acute and chronic non-A, non-B post-transfusion hepatitis. European Journal of Epidemiology, 1992, 8, 580-584.  | 2.5 | 2         |
| 112 | The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology, 2006, 44, 825. | 1.8 | 2         |
| 113 | Liver Disease and Pathology in Hemophilia. Scandinavian Journal of Haematology, 1984, 33, 341-348.  | 0.0 | 2         |
| 114 | The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: Should we utilize more?. Hepatology, 2009, 49, n/a-n/a.   | 3.6 | 2         |
| 115 | 934 DIFFERENCES IN HCV GENOTYPE 1 RVR RATES AMONG CLINICAL TRIALS IN EUROPE DEPEND ON HCV RNA ASSAY SENSITIVITY. Journal of Hepatology, 2012, 56, S364.   | 1.8 | 2         |
| 116 | Predictors of Psychopathological Outcome During Peg-Interferon and Ribavirin Therapy in Patients with Chronic HCV-Related Hepatitis. Journal of Interferon and Cytokine Research, 2013, 33, 9-14.                           | 0.5 | 2         |
| 117 | HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin. Journal of Hepatology, 2016, 65, 1058-1059.  | 1.8 | 2         |
| 118 | Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 226-227.   | 1.9 | 2         |
| 119 | Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. Antiviral Therapy, 2007, 12, 1033-40.   | 0.6 | 2         |
| 120 | TT Virus Is Present in a High Frequency of Italian Hemophilic Patients Transfused With Plasma-Derived Clotting Factor Concentrates. Blood, 1999, 94, 4333-4336.   | 0.6 | 1         |
| 121 | Left ventricular strain predicts subclinical atherosclerosis in nonadvanced nonalcoholic fatty liver disease patients. European Journal of Gastroenterology and Hepatology, 2022, Publish Ahead of Print, .                 | 0.8 | 1         |
| 122 | Is a 24-week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?. Journal of Viral Hepatitis, 2008, 15, 471-471.   | 1.0 | 0         |
| 123 | Should individuals who have been cured of hepatitis C virus and their partners be allowed to donate blood?. Lancet Haematology, 2021, 8, e8-e10.  | 2.2 | 0         |
| 124 | Intrafamilial spread of hepatitis B virus infection. Research in Clinic and Laboratory, 1981, 11, 151-8.  | 0.3 | 0         |
| 125 | Cryptic hepatitis B virus replication during prednisone therapy in type B chronic active hepatitis. Research in Clinic and Laboratory, 1987, 17, 221-227.   | 0.3 | 0         |